PGx
Pharmacogenomics Testing Service
Pharmacogenomics (PGx), the study of gene variants associated with drug metabolism, has provided new insights into how a person’s genetic profile can affect their response to treatment. Modern medicine is slowly shifting from a “one-size-fits-all” approach to a more personalized approach with therapies tailored to a particular patient type or population.
Personalized medicine, based on pharmacogenomic testing, now enables clinicians to make informed therapeutic decisions for improved medical management. This means that you can design treatments specifically for each individual, based on their genetic makeup. As a result, patients can experience better outcomes and fewer side effects.
Benefits of PGx Testing
- Improved Clinical Efficacy
- Reduced Risk of Adverse Reactions
- Individualized Dosage Regimen
- Lower Overall Medical Expenses
Our PGx Testing Panels
Galenvs Sciences Inc. is one of the leading providers of personalized medicine services, offering pharmacogenomics services for companies and healthcare providers with specific and custom panels of genes listed by the US FDA and The Clinical Pharmacogenetics Implementation Consortium (CPIC®). We are committed to helping our customers provide the best possible care, and our cutting-edge services are the perfect solution to achieve your personalized medicine goals.
Extensive Panel
The PGx Extensive Panel from Galvens is the most comprehensive pharmacogenetic testing available, analysing 74 genes in the PharmGKB list of Very Important Pharmacogenes (VIP). With high-level evidence and clinically actionable guidelines for these genes, this panel provides invaluable insights into how patients will respond to medication, helping to ensure the safest and most effective treatment possible.
Genes included:
ABCB1, ABCG2, ABL1, ACE, ADRB2, ALK, ANKK1, APOE, ATIC, ATM, BCHE, BCR, BRAF, CACNA1S, CES1, CFTR, COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, DRD2, EGFR, ERBB2, ERCC1, F2, F5, FCGR3A (CD16A), FKBP5, G6PD, GGCX, GRIK4, GSTP1, HLA-A, HLA-B, HLA-C, HLA-DPB1, HMGCR, HTR1A, HTR2A, HTR2C, IFNL3 (IL28B), IFNL4, ITPA, KIF6, KIT, KRAS, MT-RNR1, MTHFR, NAT2, NQO1, NRAS, NUDT15, OPRM1, RYR1, SLC19A1, SLC6A4, SLCO1B1, TNF, TPMT, TYMS, UGT1A1, UGT1A4, UGT2B15, VDR, VKORC1, XRCC1, rs12777823
Custom Panel
This panel offers the ability to select custom genes from the FDA and CPIC lists. Whether you are conducting research or treating patients, you can now avail of genomic analysis for known gene-drug interaction pairs in various therapeutic areas to make the best decisions for enhanced healthcare.
Genes included:
Any genes listed by the FDA and the Clinical Pharmacogenetics Implementation Consortium (CPIC®)
FDA’s Pharmacogenomic Biomarkers in Drug Labeling
CPIC® Gene Drug Pairs